Aclaris Therapeutics Inc (ACRS)

개요 뉴스 가격 이력 옵션 체인 Financials ACRS 왜 하락? 토론 예측

왜 Aclaris Therapeutics Inc (ACRS) 주가가 하락하고 있습니까?

2026-07-16 거래 세션 동안 Aclaris Therapeutics Inc(ACRS) 주식이 5.09% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!

2023-11-13:

Aclaris Therapeutics Stock (ACRS) dropped by 86.44% from $4.755 to $0.6449 in the trading on Monday November 13, 2023. The reason why ACRS stock down today is due to topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to severe rheumatoid arthritis.

Citing topline data at 12 weeks, patients who received either 20mg or 50mg doses of oral zunsemetinib didn’t meet the main endpoint called ACR20 or any secondary endpoints.
Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.